{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000144","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.109695+00:00","generated_at":"2026-05-29T02:25:35.902308+00:00","sec_items":[],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Editas Medicine CMO Baisong Mei steps down; separation terms outlined","bullets":["Baisong Mei to step down as CMO effective Dec 31, 2024; transition period ends Jan 31, 2025.","Separation agreement provides 12 months base salary, COBRA contributions, and potential 2024 bonus.","Vested stock option exercise extended to Dec 31, 2025; unvested RSUs vest through 90 days post-separation.","Agreement includes standard release, non-disparagement, and confidentiality clauses."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000144","json":"https://secwatch.observer/filing/0001650664-24-000144.json","markdown":"https://secwatch.observer/filing/0001650664-24-000144.md","text":"https://secwatch.observer/filing/0001650664-24-000144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/0001650664-24-000144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/edit-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:25:35.902308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}